For the first quarter of 2025, electroCore's net sales totaled $6.7 million compared to$5.4 million in the same period of 2024, a 23% year-over-year increase. The $1.3 million increase was driven primarily by higher sales of prescription (Rx) gammaCore sold into United States Department of Veterans Affairs (VA), growth in international markets and continued traction with Truvagawellness products. Exhibit 99.1 electroCore Announces First Quarter 2025 Financial Results First quarter 2025 net sales of$6.7 mi ...